SGCD

SGCD encodes delta-sarcoglycan, a 35-kDa structural component of the sarcoglycan-sarcospan subcomplex within the dystrophin-associated protein complex at the muscle membrane, where loss-of-function mutations cause limb-girdle muscular dystrophy type 2F (PMID:8841194). SGCD is required for assembly and sarcolemmal localization of the entire sarcoglycan-sarcospan complex: its absence in knockout mice and in naturally occurring canine LGMD2F leads to loss or destabilization of the other sarcoglycan subunits and sarcospan (PMID:31689918, PMID:28697784). Without an intact complex, the dystrophin-associated glycoprotein complex is destabilized at the sarcolemma, rendering muscle fibers vulnerable to contraction-induced damage and driving inflammatory infiltration, fibrosis, and impaired force generation through early dysregulation of the ATX-LPA and YAP/TAZ signaling axes (PMID:40050938). In the heart, SGCD-deficient cardiomyopathy proceeds through a mechanism distinct from dystrophin deficiency, without upregulation of GRK2 or NF-κB (PMID:30782477).

1. 1996 Medium

   Established SGCD as a distinct gene encoding a structural membrane component and linked its loss to human muscular dystrophy, answering what disease the gene causes and where its product acts.

   Evidence Chromosomal mapping and sequencing identifying a homozygous frameshift mutation causing LGMD2F, with complex membership inferred from co-localization

   PMID:8841194

   Open questions at the time

   • Complex membership inferred from co-localization rather than direct biochemical reconstitution
   • Structural role within the complex not resolved at residue level
2. 2017 Medium

   Demonstrated in an independent species that SGCD is required for sarcolemmal localization of the whole sarcoglycan-sarcospan complex, confirming its assembly-anchoring role beyond a single human pedigree.

   Evidence Whole exome sequencing and immunostaining/immunohistochemistry of muscle from Boston terriers with SGCD-mutant LGMD2F

   PMID:28697784

   Open questions at the time

   • Does not define which subunit interactions SGCD directly mediates
   • Mechanism of complex destabilization not dissected
3. 2018 Medium

   Distinguished SGCD-deficient cardiomyopathy from dystrophin deficiency by showing it does not engage the GRK2/NF-κB adrenergic dysregulation pathway, refining the cardiac mechanism.

   Evidence AAV9 βARKct gene therapy and molecular analysis of GRK2/NF-κB in Sgcd-/- mice with echocardiography

   PMID:30782477

   Open questions at the time

   • Positive driver of the cardiac phenotype not identified
   • Why βARKct gives mild benefit despite absent GRK2 upregulation unexplained
4. 2019 Medium

   Extended the complex-stabilizing requirement to non-muscle (retinal) tissue, showing SGCD loss collapses partner subunit expression with selective α-sarcoglycan compensation.

   Evidence Immunofluorescence, Western blot, and electroretinography in Sgcd-/- mouse retina

   PMID:31689918

   Open questions at the time

   • Functional consequence of complex loss in retina incompletely defined
   • Basis of selective α-sarcoglycan compensation unknown
5. 2025 Medium

   Connected SGCD loss to specific downstream signaling, identifying early ATX-LPA and YAP/TAZ dysregulation as drivers of inflammation, fibrosis, and mechanical fragility in skeletal muscle.

   Evidence Sgcd-/- mouse contractile, pathway, inflammatory, and fibrotic readouts across multiple muscles at 1 and 2 months

   PMID:40050938

   Open questions at the time

   • Causal link between complex loss and ATX-LPA/YAP/TAZ activation not mechanistically resolved
   • Whether targeting these pathways rescues phenotype untested

• How SGCD physically organizes the sarcoglycan-sarcospan complex and how complex loss is transduced into specific signaling cascades remain open.
• No structural model of SGCD within the complex
• Direct binding partners within the complex not mapped biochemically
• Mechanistic chain from sarcolemmal instability to ATX-LPA/YAP/TAZ unestablished